Policy | May 09, 2026
NIPER, Raebareli signs technology transfer pact with Lofty Laboratories
Academia-industry partnership to promote indigenous technology commercialization in biotech sector
Academia-industry partnership to promote indigenous technology commercialization in biotech sector
The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
The company secured new accounts, including ACCESS-PVI trial sites, and aims to strengthen global commercialization efforts
The private funding rose 38% amid growing international collaborations and CDMO demand
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Precision medicine company advances Raman spectroscopy-based therapeutic drug monitoring platform for rapid, patient-specific dosing solutions
Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
The 4,000-square-foot facility is designed as a hands-on hub where customers can work directly with scientists and engineers
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
Subscribe To Our Newsletter & Stay Updated
